By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nektar Therapeutics (CA) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


SEARCH JOBS

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™(naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a wholly-owned new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer. In hemophilia, BAX 855, a longer-acting PEGylated Factor VIII therapeutic is in Phase 3 development conducted by partner Baxter. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

The company was founded in 1990 and is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.




Key Statistics


Email: nektar@nektar.com
Ownership: Public

Web Site: Nektar Therapeutics
Employees: 429
Symbol: NKTR
 









Company News
Bristol-Myers Squibb (BMY) And Nektar Therapeutics (NKTR) Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo(Nivolumab) And NKTR-214 9/27/2016 11:07:34 AM
Nektar Therapeutics (NKTR) To Host Investor & Analyst Conference Call To Discuss New Clinical Collaboration With Bristol-Myers Squibb (BMY) 9/27/2016 10:06:30 AM
Juno (JUNO), Nektar Therapeutics (NKTR) CEOs Sold $1 Million of Stock Before Labor Day 9/9/2016 6:04:31 AM
Nektar Therapeutics (NKTR) Reports Financial Results For The Second Quarter Of 2016 8/4/2016 7:56:45 AM
Nektar Therapeutics (NKTR) To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets 7/28/2016 8:51:59 AM
ASCO2016: Nektar Therapeutics (NKTR) Release: Preclinical Data Presented At ASCO 2016 Annual Meeting Demonstrate That Single-Agent NKTR-214 Produces A Large Increase In Tumor-Infiltrating Lymphocytes To Provide Durable Anti-Tumor Activity 6/7/2016 9:22:49 AM
Bay Area's Nektar Therapeutics (NKTR) Names a New CFO and COO 6/3/2016 5:54:59 AM
Nektar Therapeutics (NKTR), DAIICHI SANKYO EUROPE GmbH Strike $80 Million+ ONZEALD Pact 6/1/2016 6:41:03 AM
Nektar Therapeutics (NKTR) Reports Financial Results For The First Quarter Of 2016 5/4/2016 7:01:41 AM
Nektar Therapeutics (NKTR) To Announce Financial Results For The First Quarter 2016 On Tuesday, May 3, 2016, After Close Of U.S.-Based Financial Markets 4/28/2016 7:04:38 AM
12345678910...
//-->